免疫治疗联合靶向治疗对晚期肝癌患者血清HIF-1α、VEGF、AFP、PHD2水平的影响  

Effect of Immunotherapy Combined with Targeted Therapy on Serum HIF-1α,VEGF,AFP and PHD2 Levels in Patients with Advanced Liver Cancer

作　　者：刘小梅 LIU Xiaomei(The Third People’s Hospital of Jiujiang City,Jiangxi Province,Jiujiang 332000,China)

机构地区：[1]江西省九江市第三人民医院,江西九江332000

出　　处：《中国医学创新》2022年第34期1-4,共4页Medical Innovation of China

基　　金：江西省卫生健康委科技计划项目(SKJP220210377)。

摘　　要：目的:探讨帕博利珠单抗免疫治疗联合仑伐替尼分子靶向治疗晚期肝癌患者的效果及对患者血清缺氧诱导因子-1α(HIF-1α)、甲胎蛋白(AFP)、脯氨酸羟化酶2(PHD2)、血管表皮生长因子(VEGF)水平的影响。方法:选取2019年2月-2022年2月在九江市第三人民医院接受治疗的晚期肝癌患者56例,按照随机数字表法分为对照组和研究组,每组28例。对照组接受帕博利珠单抗免疫治疗,研究组接受帕博利珠单抗免疫治疗联合仑伐替尼分子靶向治疗。观察比较两组治疗前及治疗2个月后血清HIF-1α、VEGF、AFP、PHD2水平和临床总有效率。结果:与治疗前比较,治疗2个月后两组血清AFP、VEGF、HIF-1α、PHD2水平均降低,差异均有统计学意义(P<0.05)。与对照组比较,研究组治疗2个月后VEGF、HIF-1α、AFP、PHD2水平均较低,差异均有统计学意义(P<0.05);研究组临床总有效率(96.43%)高于对照组(75.00%),差异有统计学意义(P<0.05)。结论:帕博利珠单抗免疫治疗联合仑伐替尼分子靶向治疗可降低晚期肝癌患者血清AFP、VEGF、HIF-1α、PHD2水平,提高临床疗效。Objective:To investigate the efficacy of Pembrolizumab immunotherapy combined with molecular targeted therapy of Lenvatinib in patients with advanced liver cancer and the effects on serum hypoxiainducible factor-1α(HIF-1α),alpha-fetoprotein(AFP),proline hydroxylase 2(PHD2),vascular epidermal growth factor(VEGF)levels.Method:A total of 56 patients with advanced liver cancer who were treated in the Third People’s Hospital of Jiujiang City from February 2019 to February 2022 were selected and randomly divided into a control group and a study group according to the random number table method,with 28 cases in each group.The patients in the control group received Pembrolizumab immunotherapy,and the patients in the study group received Pembrolizumab immunotherapy combined with Lenvatinib molecular targeted therapy.The levels of serum HIF-1α,VEGF,AFP and PHD2 before and after treatment and total efficiency in two groups were observed and compared.Result:Compared with before treatment,the levels of serum AFP,VEGF,HIF-1αand PHD2 in two groups were decreased after 2 months of treatment,the differences were all statistically significant(P<0.05).Compared with the control group,the levels of VEGF,HIF-1α,AFP and PHD2 in the study group after 2 months of treatment were lower,the differences were all statistically significant(P<0.05).The total clinical effective rate of the study group(96.43%)was higher than that of the control group(75.00%),the difference was statistically significant(P<0.05).Conclusion:Immunotherapy with Pembrolizumab combined with molecular targeted therapy with Lenvatinib can reduce the levels of serum AFP,VEGF,HIF-1αand PHD2 in patients with advanced liver cancer,and improve the clinical efficacy.

关 键 词：肝癌晚期 免疫治疗 靶向治疗 血管表皮生长因子 缺氧诱导因子-1Α 

分 类 号：R735.7[医药卫生—肿瘤]